How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bipolar-affective-disorder-current-episode-depression.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bipolar affective disorder, current episode depression — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bipolar affective disorder, current episode depression (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bipolar affective disorder, current episode depression, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Latuda	LURASIDONE	Sunovion Pharms Inc	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2010-01-01
Prozac	fluoxetine	Eli Lilly and Company	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Prozac	Prozac	RenJi Hospital		Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A
Seroquel	Seroquel	University of Pittsburgh		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Quetiapin	Quetiapin	Sykehuset Innlandet HF		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Seroquel	quetiapine	AstraZeneca		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa	Zyprexa	Washington University School of Medicine		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa	olanzapine	Eli Lilly	Atypical Antipsychotic [EPC]	Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Bipolar affective disorder, current episode depression
AstraZeneca · 1 drug in Bipolar affective disorder, current episode depression
Eli Lilly · 1 drug in Bipolar affective disorder, current episode depression
Eli Lilly and Company · 1 drug in Bipolar affective disorder, current episode depression
RenJi Hospital · 1 drug in Bipolar affective disorder, current episode depression
Sunovion Pharms Inc · 1 drug in Bipolar affective disorder, current episode depression
Sykehuset Innlandet HF · 1 drug in Bipolar affective disorder, current episode depression
University of Pittsburgh · 1 drug in Bipolar affective disorder, current episode depression
Washington University School of Medicine · 1 drug in Bipolar affective disorder, current episode depression

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bipolar affective disorder, current episode depression:

Cite this brief

Drug Landscape (2026). Bipolar affective disorder, current episode depression — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bipolar-affective-disorder-current-episode-depression. Accessed 2026-06-10.

Bipolar affective disorder, current episode depression full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing